A sweeping recall of 42 distinct batches of antihypertensive medications has been enforced by the United States’ primary healthcare authority, the Food and Drug Administration (FDA). This massive recall operation follows the alarming revelation of the presence potentially carcinogenic elements across numerous medications produced by as many as five pharmaceutical giants.
This comprehensive recall operation came into effect post the discovery of worrying traces of azidomethyl biphenyl tetrazole (AZBT) impurities within certain batches of a popular hypertension drug known as irbesartan. The finding was alarming enough to prompt immediate action by the FDA, as articulated in a statement by the acting secretary-general of the division, Narong Aphikulvanich.
The statement emphasized the chief cause driving the recall – the increased risk to patients of developing cancer due to these impurities, news that understandably has caused quite a sensation. However, Narong was quick to assure consumers that the recall was limited to particular batches of irbesartan, with all other FDA-endorsed models of the drug being absolutely safe to consume.
In the aftermath of this troubling discovery, the FDA swiftly acted, proceeding to initiate a comprehensive series of standard inspections across all manufacturers of irbesartan for the presence of any AZBT impurities. Furthermore, manufacturers have also been mandated to switch any contaminated ingredients with safer, non-AZBT alternatives and to reassess their distribution strategies for the medication. This information was reported by Bangkok Post.
The FDA’s stringent call to action was triggered by a comprehensive survey of irbesartan samples sourced directly from the manufacturers. It was the subsequent evaluation by the Department of Medical Sciences that revealed surprising levels of AZBT impurities in certain models of the medication; levels that exceeded international safety norms, and thereby increased the risk of cancer.
Simultaneous with issuing the manufacturer directives, the FDA moved to begin the process of retrieving the 42 affected batched of irbesartan from multiple channels of healthcare, including hospitals, clinics, pharmacies, and drug manufacturing premises. However, Narong advised against patients discontinuing the use of the drug suddenly due to potential hypertension-related complications and instead encouraged them to vigilantly inspect their current stock of medication.
The five pharmaceutical behemoths implicated in the unsavory discovery of contaminants in their irbesartan products were identified as TO Chemicals Co Ltd, Siam Bheasach Co Ltd, M&H Manufacturing Co Ltd, the Government Pharmaceutical Organisation, and Sriprasit Pharmacy Co Ltd.
In a separate, recent development, the regulatory body conducted an investigation into a popular herbal drink from The Phi (เทพี) brand, a name translating to “goddess” in Thai language. This drink, which has been marketed for its supposed multi-purpose benefits, including combating various health issues such as allergies, disk herniation, and rheumatoid arthritis, was found to contain steroids, quite a shocking discovery that led to another critical inquiry.
To keep up with more of these essential stories from the ever-evolving world of pharmaceuticals and healthcare, follow the latest updates from The Thaiger on our dedicated Facebook page. Simply click [HERE](#) to access it and stay one step ahead!